{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Capture the number of adverse events experienced when combining thalidomide, lenalidomide, and rituximab in patients with previously treated WM","groups":[{"description":"Daily alternating thalidomide and lenalidomide plus rituximab (ThRiL) in patients with previously treated WM\n\nThalidomide: Thalidomide 50 mg (every ODD day of a 28 day cycle: Days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 \\& 27)\n\nLenalidomide: Lenalidomide (every EVEN day of a 28 day cycle: Days 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 \\& 28). Lenalidomide will be initiated at a starting dose of 5 mg.\n\nRituximab: Rituximab 375 mg/m2 IV on Days 1, 8, 15 and 22 (+/- 2 days) and then again on the same weekly x 4 schedule every 6th cycle thereafter (Cycle 7, 13, 19, etc).","id":"OG000","title":"All Patients"}],"populationDescription":"Data was not collected due to early termination.","reportingStatus":"POSTED","timeFrame":"approximately 24 months per patient","title":"Number of Adverse Events Experienced With Alternating Thalidomide and Lenalidomide Plus Rituximab for Subjects With Previously Treated Waldenstrom's Macroglobulinemia","type":"SECONDARY"}